Although no improvement in PFS was demonstrated and a low ORR was observed, pembrolizumab monotherapy demonstrated superior median OS in the programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥ 20 population (14.9 months vs. 10.7 months) compared with the EXTREME regimen in patients with R/M SCCHN (7). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.